Brought to you by 
Adolor gets rights to Roberts' gastrointestinal agent
13 May 2013
Executive Summary
Analgesics biopharmaceutical Adolor Corp. has acquired a 13-month worldwide option to Roberts Pharmaceutical's (acquires and develops late-stage drugs) LY246736 (now called ADL 8-2698) compound for the prevention of opiate-induced constipation.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adolor gets rights to Roberts' gastrointestinal agent
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice